Daewoong Pharmaceutical presented new treatment options for patients with dyslipidemia through its combination drug BaroEjet (Pitavastatin 1mg and Ezetimibe 10mg) during a recent symposium. The event focused on sharing clinical data and discussing tailored treatment strategies for various patient groups, confirming the practical applicability of these strategies in clinical settings.
On June 1, Daewoong Pharmaceutical announced the conclusion of the BaroEjet launch symposium, which took place over April in Busan, Gyeongju, and Seoul.
The event was attended by 210 medical professionals nationwide and centered on sharing the results of BaroEjet's Phase 3 clinical trials while proposing customized treatment strategies for different patient groups. The discussion included a wide range of patients, from those at low to moderate risk to those at very high risk.
BaroEjet specifically targets the low to moderate risk group, which comprises over 70% of the adult population in South Korea. The importance of early LDL cholesterol management was emphasized, particularly for patients with prediabetes or metabolic disorders, as they may face increased cardiovascular risks.
The Phase 3 clinical trial results were also revealed. In a study involving 129 patients with primary hypercholesterolemia in South Korea, BaroEjet demonstrated a 43.9% reduction in LDL cholesterol after eight weeks, significantly outperforming the single-agent Pitavastatin (29.1%).
The drug's characteristics were highlighted as strengths. Pitavastatin has a low interaction burden with CYP enzyme-based medications, making it relatively safe for patients on multiple drugs. Additionally, it poses a lower risk of new diabetes onset compared to other statins, reducing the burden of blood sugar management. Daewoong Pharmaceutical explained that BaroEjet is an option that considers both achieving LDL-C targets and long-term medication adherence.
For high-risk treatment strategies, rapid LDL-C reduction is crucial for patients with atherosclerotic cardiovascular disease (ASCVD) or acute coronary syndrome (ACS), with the rosuvastatin and ezetimibe combination drug Crezet being a primary option. In patients with chronic kidney disease (CKD), the potential use of atorvastatin-based Litovajet was discussed due to its lower renal excretion dependency.
In patients with mixed dyslipidemia, managing residual cardiovascular risk was emphasized. For those with elevated triglycerides and low HDL-C, the combination of Pitavastatin and Fenofibrate, known as Barofen, was presented as a means to simultaneously reduce LDL-C, lower triglycerides, and improve HDL-C.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.